Research

Hormonal

GLP-1 receptor agonists (semaglutide, tirzepatide) and bariatric surgery (RYGB) extend the duration of weight loss prior to plateau by weakening the physiological appetite feedback control circuit, whereas diet restriction fails to weaken this circuit and thus plateaus within ~12 months.

If you are using GLP-1s or had surgery, your prolonged weight loss is due to a physiological change in how your body regulates appetite, not just willpower. Dieting alone triggers a strong appetite feedback loop that causes early plateaus; these interventions bypass that loop.

ModerateSupportsMEDIUM confidence
Preliminary results suggest that, unlike diet restriction, semaglutide, tirzepatide, and RYGB weaken the appetite feedback control circuit by ~40–70% thereby resulting in an extended period of weight loss prior to the plateau.
Kevin D. Hall · Obesity · 2024

Why this rating

Based on mathematical modeling of published trial data, not a new primary clinical trial.

Source

Physiology of the weight‐loss plateau in response to diet restriction, <scp>GLP‐1</scp> receptor agonism, and bariatric surgery

Kevin D. Hall · Obesity · 2024

DOI 10.1002/oby.24027

mechanism_onlyCited 32×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →